Barclays Reiterates Buy Rating on Hims & Hers Health
Barclays maintains its Buy rating with a $39 target for Hims & Hers Health, a 17.58% upside from the current price.
Key Points
- Barclays reiterated its Buy rating on Hims & Hers Health, Inc. (NYSE:HIMS) with a $39 price target on June 18, 2026.
- Barclays's $39 price target implies 17.58% upside from Hims & Hers Health, Inc.'s ($HIMS) current $33.17 share price.
- Shares of HIMS traded near $31.89, with a market cap of about $7.38 billion and a forward P/E of 35.83.
- Insider activity included planned sales by the CTO and PAO, while several major funds adjusted their holdings recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclays has reiterated its Buy rating on Hims & Hers Health, Inc. (NYSE:HIMS) with a price target of $39. This update was announced on June 18, 2026. Analyst Glen Santangelo maintained the positive outlook, suggesting confidence in the company's future performance.
Hims & Hers Health, Inc. Stock Up 15.0%
Shares of NYSE:HIMS traded near $31.89. The company has a market cap of approximately $7.38 billion and a forward P/E ratio of 35.83, showing investor expectations for future earnings growth. Hims & Hers Health has a 52-week low of $13.74 and a high of $70.43, with a 50-day moving average of $26.32 and a 200-day moving average of $33.39. The stock's beta is 2.398, indicating higher volatility compared to the market.
$HIMS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Hims & Hers Health, Inc.
Recent insider activity at Hims & Hers Health includes several planned sales. On June 17, 2026, CTO Mohamed Elshenawy sold 30,040 shares at an average price of $31.50, while PAO Irene Becklund sold 4,490 shares at the same price. COO Michael Chi also sold 14,027 shares on the same day. Earlier, on June 15, Elshenawy bought 282,597 shares, and Chief Legal Officer Soleil Boughton sold 42,261 shares.
Analysts Set New Price Targets
On June 18, 2026, Barclays maintained its Buy rating on Hims & Hers Health with a $39 price target. Other analysts have varied views, with B of A Securities maintaining a Hold rating and a $25 target on May 26, 2026, and Truist Securities also holding a Hold rating with a $23 target on May 22, 2026. The consensus among 14 analysts is a Hold recommendation, with a mean price target of $26.61.
About Hims & Hers Health
Hims & Hers Health, Inc. is a health and wellness platform based in San Francisco, California. The company connects consumers with licensed healthcare professionals and offers a range of health and wellness products and services. These include prescription and non-prescription products available online and in stores, focusing on general wellness, skincare, sexual health, and hair care. The company also provides medical consultations and laboratory testing services.
Bottom Line
Barclays' reiteration of a Buy rating and a $39 price target for Hims & Hers Health underscores continued confidence in the company's potential. Investors often track analyst ratings as they can influence market perceptions. It's important to remember that these ratings are based on past data and may not reflect the company's current or future performance.
Get Hims & Hers Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $HIMS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.